 Patients with non-ABC subtype determined by gene expression profiling will be allocated to Arm A while patients with ABC activated B-cell type subtype will be allocated to Arm B. Approximately 120 patients may be enrolled and assigned into the appropriate treatment arms dependent upon their cell of origin status. 